1224103-64-3

Upstream product

• 186581-53-3 diazomethane 
• 1224103-63-2 ethyl (2E)-3-(3,5-difluoro-4-hydroxyphenyl)prop-2-enoate 
• 70-25-7 N-Methyl-N'-nitro-N-nitrosoguanidine 
• 1609289-02-2 (E)-3-(4-benzyloxy-3,5-difluorophenyl)acrylic acid ethyl ester 
• 125036-88-6 4-(benzyloxy)-3,5-difluorobenzaldehyde 
• 1224103-65-4 2-(4-benzyloxy-3,5-difluorophenyl)cyclopropanecarboxylic acid ethyl ester 
• 28177-48-2 2,6-difluorophenol 
• 118276-06-5 3,5-difluoro-4-hydroxybenzaldehyde 
• 104197-13-9 4-bromo-2,6-difluorophenol 
• 140-88-5 ethyl acrylate 

Downstream Products

• 1224103-65-4 2-(4-benzyloxy-3,5-difluorophenyl)cyclopropanecarboxylic acid ethyl ester 
• 1224103-66-5 (2-(4-(benzyloxy)-3,5-difluorophenyl)-cyclopropyl)methanol 
• 1224103-67-6 C₁₇H₁₄F₂O₂ 
• 1234844-98-4 C₁₉H₁₈F₂O₂ 
• 1224103-87-0 C₁₈H₁₆F₂O₂ 
• 1224103-88-1 C₁₈H₁₆F₂O₃ 
• 1224103-89-2 ethyl 2-(2-(4-(benzyloxy)-3,5-difluorophenyl)cyclopropyl)acetate 
• 1224103-68-7 ethyl 2-(2-(3,5-difluoro-4-hydroxyphenyl)cyclopropyl)acetate 

Relevant academic research and scientific papers

Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

THIOARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF

Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.